Calendar

The first post-print read is mixed: Q3 revenue and 2026 guidance rose, but MedTech missed management's expectations and JNJ closed October 13 at $248.61, down 5.73%. Coverage linked the selloff to the talc charge and MedTech weakness. No reliable post-print analyst target-change series is available, and conflicting consensus snapshots limit surprise precision; zero values in unobserved sentiment fields are placeholders, not measured readings. [historical close](https://chartexchange.com/symbol/nyse-jnj/historical/) [market coverage](https://uk.investing.com/news/stock-market-news/why-is-johnson--johnson-stock-tumbling-7-today-93CH-4908312)

The October 9 close of $82.17 was nearly flat versus October 8 despite the earnings miss and guidance cut; the October 13 anchor of $79.57 is about 3.2% lower. That later decline cannot be attributed solely to earnings because fuel-cost headlines also affected airlines. One verified post-print target cut is available, but a comprehensive estimate-revision set is not. Social, options, short-interest and employee metrics were not supplied; zero entries in the sentiment object mean unavailable, not neutral observations. [Historical closes](https://stockanalysis.com/stocks/dal/history/) [October 9 market coverage](https://www.kiplinger.com/investing/stocks/stocks-climb-a-wall-of-worry-ahead-of-earnings-stock-market-today) [UBS revision coverage](https://ca.investing.com/news/stock-market-news/ubs-cuts-delta-air-lines-stock-price-target-on-higher-costs-93CH-4876493)

News tone is mixed: company-reported Q3 growth and an earnings beat contrast with a 5.6% October 13 closing-price fall to $124.53. Zacks' $2.66 EPS and $23.66 billion revenue consensus imply a beat, but the available UBS target cut was pre-print, not a post-print revision. No reliable post-print estimate-change series, options skew, short-interest or social-coverage measure was supplied; zeroes in the sentiment object denote unavailable data, not neutral readings. [#SEC-8K-2026-10-13]

Stored secondary coverage reports a 3.7% gain on the October 8 release day, yet the October 12 RankAlpha anchor is $126.68; the initial positive reaction should not be extrapolated. The revenue/EPS beat contrasts with the company’s profit-guidance reduction and subsequent reported target cuts. The sentiment fields set to zero above are unavailable measurements, not neutral observations; social coverage is absent. https://finance.yahoo.com/markets/stocks/articles/pepsico-just-reported-earnings-heres-144624494.html

The scheduled October 8 earnings date appears inconsistent with the confirmed September 29 company release; no separate October 8 company print was verified. INTG fell from $32.90 on September 28 to $29.78 on September 30, then recovered to the $32.72 October 12 anchor; price movement alone does not establish its cause. https://stockanalysis.com/stocks/intg/history/ No reliable post-print consensus surprise, target changes, or estimate revisions were verified. The positive deterministic delta prior reflects better reported hotel results, but thin coverage and earnings-quality questions keep conviction moderate.

The earnings release supports a more constructive view than the negative pre-print baseline, but price action was uneven: HELE closed at $26.55 on October 8 after reaching $31.98 intraday, held near $26.51 on October 9, then closed at the $28.49 anchor on October 12—about 11.5% above its October 7 close. A reported UBS target increase is a modest revision signal, not a broad analyst endorsement. Social, options, short-interest and employee measures are unavailable; zero fields indicate missing data, not neutral readings. [Historical prices](https://stockanalysis.com/stocks/hele/history/) [UBS target coverage](https://uk.investing.com/news/stock-market-news/ubs-raises-helen-of-troy-stock-price-target-to-29-on-earnings-beat-93CH-4903280)